Clearside Biomedical Inc
CLSD0.410USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
2.15MMarket Cap
LossP/E TTM
More Details of Clearside Biomedical Inc Company
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Clearside Biomedical Inc Info
Ticker SymbolCLSD
Company nameClearside Biomedical Inc
IPO dateJun 02, 2016
CEO- -
Number of employees32
Security typeOrdinary Share
Fiscal year-endJun 02
Address900 North Point Parkway
CityALPHARETTA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code30005
Phone16782703631
Websitehttps://clearsidebio.com/
Ticker SymbolCLSD
IPO dateJun 02, 2016
CEO- -
Company Executives of Clearside Biomedical Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Charles A. Deignan
Mr. Charles A. Deignan
Principal Financial Officer
Principal Financial Officer
24.87K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Director
Independent Director
6.20K
--
Dr. Christy L. Shaffer, Ph.D.
Dr. Christy L. Shaffer, Ph.D.
Independent Director
Independent Director
5.23K
--
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Independent Director
3.40K
--
Dr. Benjamin (Ben) Yerxa, Ph.D.
Dr. Benjamin (Ben) Yerxa, Ph.D.
Independent Director
Independent Director
1.20K
--
Dr. George Lasezkay, Pharm.D.
Dr. George Lasezkay, Pharm.D.
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Jenny Kobin
Ms. Jenny Kobin
Investor Relations
Investor Relations
--
--
Mr. Clay Bernardin Thorp
Mr. Clay Bernardin Thorp
Chairman of the Board
Chairman of the Board
--
--
Mr. Jeffrey L. (Jeff) Edwards
Mr. Jeffrey L. (Jeff) Edwards
Independent Director
Independent Director
--
--
Dr. Victor Chong
Dr. Victor Chong
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Charles A. Deignan
Mr. Charles A. Deignan
Principal Financial Officer
Principal Financial Officer
24.87K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Director
Independent Director
6.20K
--
Dr. Christy L. Shaffer, Ph.D.
Dr. Christy L. Shaffer, Ph.D.
Independent Director
Independent Director
5.23K
--
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Independent Director
3.40K
--
Dr. Benjamin (Ben) Yerxa, Ph.D.
Dr. Benjamin (Ben) Yerxa, Ph.D.
Independent Director
Independent Director
1.20K
--
Dr. George Lasezkay, Pharm.D.
Dr. George Lasezkay, Pharm.D.
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Whitmore (Bradford T)
5.44%
Wiles (Stephen Boyd)
5.10%
The Vanguard Group, Inc.
4.24%
Grace Brothers Management, LLC
2.87%
Carmignac Gestion
1.92%
Other
80.43%
Shareholders
Shareholders
Proportion
Whitmore (Bradford T)
5.44%
Wiles (Stephen Boyd)
5.10%
The Vanguard Group, Inc.
4.24%
Grace Brothers Management, LLC
2.87%
Carmignac Gestion
1.92%
Other
80.43%
Shareholder Types
Shareholders
Proportion
Individual Investor
12.88%
Investment Advisor
6.35%
Hedge Fund
3.60%
Investment Advisor/Hedge Fund
3.45%
Bank and Trust
0.15%
Research Firm
0.02%
Other
73.54%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
108
710.65K
19.62%
-5.21K
2025Q3
114
719.90K
19.76%
-60.33K
2025Q2
112
779.03K
19.12%
+38.24K
2025Q1
113
740.79K
20.44%
-310.40K
2024Q4
119
785.73K
21.10%
-44.72K
2024Q3
122
1.07M
28.30%
-247.97K
2024Q2
124
1.46M
33.80%
-114.57K
2024Q1
123
1.57M
23.30%
+414.26K
2023Q4
126
1.06M
34.54%
-6.74K
2023Q3
136
1.06M
38.90%
-50.34K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Whitmore (Bradford T)
284.60K
5.44%
-15.07K
-5.03%
Dec 31, 2024
Wiles (Stephen Boyd)
266.90K
5.1%
+266.90K
--
Mar 31, 2025
The Vanguard Group, Inc.
224.20K
4.28%
+37.10K
+19.83%
Jun 30, 2025
Grace Brothers Management, LLC
150.30K
2.87%
-6.37K
-4.07%
Dec 31, 2024
Carmignac Gestion
100.56K
1.92%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
52.69K
1.01%
-124.00
-0.23%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
41.68K
0.8%
-10.78K
-20.55%
Jun 30, 2025
Lasezkay (George M)
25.52K
0.49%
--
--
Jun 30, 2025
Renaissance Technologies LLC
33.11K
0.63%
-3.86K
-10.44%
Jun 30, 2025
Deignan (Charles A)
24.87K
0.48%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AltShares Event-Driven ETF
0.29%
iShares Micro-Cap ETF
0%
AltShares Event-Driven ETF
Proportion0.29%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 11, 2025
Merger
15→1
Date
Type
Ratio
Sep 11, 2025
Merger
15→1
FAQs
Who are the top five shareholders of Clearside Biomedical Inc?
The top five shareholders of Clearside Biomedical Inc are:
Whitmore (Bradford T) holds 284.60K shares, accounting for 5.44% of the total shares.
Wiles (Stephen Boyd) holds 266.90K shares, accounting for 5.10% of the total shares.
The Vanguard Group, Inc. holds 224.20K shares, accounting for 4.28% of the total shares.
Grace Brothers Management, LLC holds 150.30K shares, accounting for 2.87% of the total shares.
Carmignac Gestion holds 100.56K shares, accounting for 1.92% of the total shares.
Whitmore (Bradford T) holds 284.60K shares, accounting for 5.44% of the total shares.
Wiles (Stephen Boyd) holds 266.90K shares, accounting for 5.10% of the total shares.
The Vanguard Group, Inc. holds 224.20K shares, accounting for 4.28% of the total shares.
Grace Brothers Management, LLC holds 150.30K shares, accounting for 2.87% of the total shares.
Carmignac Gestion holds 100.56K shares, accounting for 1.92% of the total shares.
What are the top three shareholder types of Clearside Biomedical Inc?
The top three shareholder types of Clearside Biomedical Inc are:
Whitmore (Bradford T)
Wiles (Stephen Boyd)
The Vanguard Group, Inc.
Whitmore (Bradford T)
Wiles (Stephen Boyd)
The Vanguard Group, Inc.
How many institutions hold shares of Clearside Biomedical Inc (CLSD)?
As of 2025Q4, 108 institutions hold shares of Clearside Biomedical Inc, with a combined market value of approximately 710.65K, accounting for 19.62% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.14%.
What is the biggest source of revenue for Clearside Biomedical Inc?
In --, the -- business generated the highest revenue for Clearside Biomedical Inc, amounting to -- and accounting for --% of total revenue.
